Why do pharmaceutical labs require elemental analysis testing?

Pharmaceutical labs require elemental analysis testing to detect and quantify toxic impurities that can enter drug products through raw materials, manufacturing equipment, or the production process itself. These impurities pose direct risks to patient safety, which is why regulatory agencies worldwide have established strict limits and made testing a mandatory part of pharmaceutical quality control. The sections below address the most common questions labs face when implementing or reviewing their elemental impurity testing programmes.

Which elemental impurities are most dangerous in pharmaceutical products?

The most dangerous elemental impurities in pharmaceutical products are those classified as highly toxic at low concentrations, including lead, arsenic, cadmium, and mercury. These elements have no therapeutic benefit and can cause serious harm even in trace amounts. Regulatory frameworks group elemental impurities by their likelihood of occurrence and their toxicological risk profile.

Beyond the four most commonly cited elements, other impurities such as cobalt, nickel, vanadium, and certain platinum-group metals are also subject to control, particularly when they may originate from catalysts used in synthesis or from processing equipment. The concern with all of these substances is that they are cumulative toxins, meaning exposure builds over time and small amounts across multiple doses can become clinically significant.

The specific risk associated with each element depends on factors including:

The route of administration of the drug product (oral, inhalation, parenteral)
The daily dose and duration of treatment
The chemical form in which the element is present
The vulnerability of the patient population

Because the route of administration significantly affects how the body absorbs these impurities, the same element may carry different risk levels depending on whether the product is a tablet, an inhaled formulation, or an injectable. Consult the applicable pharmacopeia or regulatory guidance for exact permitted daily exposure limits by route.

What regulations require elemental analysis in pharma?

Elemental analysis in pharmaceutical manufacturing is primarily required under ICH Q3D guidelines, which establish a risk-based framework for controlling elemental impurities in drug products. These guidelines have been adopted by major regulatory authorities, including the EMA, the US FDA, and health agencies across the Benelux region and broader Europe, making ICH Q3D compliance effectively mandatory for market authorisation.

Alongside ICH Q3D, pharmacopoeial standards such as those published in the European Pharmacopoeia and the United States Pharmacopeia include specific chapters dedicated to elemental impurity testing. These chapters define accepted analytical procedures and reference standards that manufacturers must follow when demonstrating compliance.

For manufacturers operating under Good Manufacturing Practice, elemental impurity testing is also embedded in broader GMP obligations around raw material characterisation, process validation, and finished product release testing. Regulatory inspections increasingly scrutinise whether elemental impurity risk assessments have been properly documented and whether testing methods have been validated.

What analytical methods are used for elemental impurity testing?

The most widely adopted analytical method for elemental impurity testing in pharmaceutical labs is ICP-MS, or inductively coupled plasma mass spectrometry. ICP-MS pharmaceutical applications are valued because the technique offers very high sensitivity across a broad range of elements simultaneously, making it well suited to detecting trace-level impurities within complex drug matrices.

ICP-OES (inductively coupled plasma optical emission spectrometry) is another commonly used technique. While it is generally less sensitive than ICP-MS, it is well established for routine quality control environments where the concentration levels being measured are somewhat higher or where throughput and cost considerations are a priority.

Both ICP-based techniques have largely replaced older methods such as atomic absorption spectrometry for multi-element screening, though atomic absorption remains in use in some labs for single-element determinations. The choice of method depends on the specific elements being monitored, the required detection limits, and the complexity of the sample preparation workflow.

When must a pharmaceutical manufacturer perform elemental analysis?

A pharmaceutical manufacturer must perform elemental analysis at several defined stages: during the initial risk assessment for a new drug product, during process validation, and as part of ongoing finished product release testing where the risk assessment identifies a need. Testing is also triggered when there are changes to raw material suppliers, manufacturing sites, or process equipment.

The ICH Q3D framework requires manufacturers to conduct a formal elemental impurity risk assessment that evaluates all potential sources of contamination. This assessment determines which elements require routine monitoring and at what frequency. If the risk assessment concludes that a particular impurity is unlikely to be present above a defined threshold, routine batch testing for that element may not be required, provided the assessment is properly documented and periodically reviewed.

Regulatory submissions for new drug applications must include documented evidence of the elemental impurity risk assessment and, where applicable, supporting analytical data from ICP-MS or equivalent methods.

How does elemental analysis fit into pharmaceutical quality control workflows?

Elemental analysis fits into pharmaceutical quality control workflows at multiple control points, from incoming raw material testing through in-process monitoring to final product release. The goal is to ensure that no single step in the manufacturing chain introduces impurities that accumulate to levels of concern by the time the product reaches the patient.

In practice, QC labs integrate elemental impurity testing alongside other release tests such as identity, purity, and microbiological testing. Sample preparation is a critical step in this workflow, since pharmaceutical matrices, including tablets, capsules, liquids, and injectables, each require specific dissolution or digestion approaches before analysis by ICP-MS or ICP-OES.

Instrument qualification and method validation are also central to QC integration. Analytical methods used for elemental impurity testing must be validated for specificity, linearity, accuracy, and precision under GMP conditions. Instrument qualification records, including IQ and OQ documentation, must be maintained to demonstrate that the analytical system is performing within its specified parameters.

What happens if elemental impurity limits are exceeded in a drug product?

If elemental impurity limits are exceeded in a drug product, the batch cannot be released for distribution. Exceedances trigger a formal out-of-specification investigation to identify the root cause, which may lie in contaminated raw materials, degraded equipment components, or a failure in the manufacturing process. The investigation must be documented and resolved before any corrective action can be validated.

Depending on the severity and the nature of the exceedance, regulatory authorities may need to be notified. For products already on the market, an exceedance discovered during stability testing or post-market surveillance can result in a product recall. The reputational and financial consequences of a recall make proactive elemental analysis testing a far more cost-effective strategy than reactive investigation.

Manufacturers are also required to implement corrective and preventive actions following any confirmed exceedance. These actions may include supplier qualification audits, equipment replacement, revised cleaning validation procedures, or updated raw material specifications.

For exact compliance limits applicable to your drug product and route of administration, consult the relevant pharmacopeia or regulatory guidance such as ICH Q3D and the European Pharmacopoeia.

How SciSPX supports elemental analysis in pharmaceutical labs

SciSPX works with pharmaceutical QC and R&D labs across the Benelux to implement and maintain elemental analysis workflows that meet current regulatory requirements. Whether a lab is setting up ICP-MS capabilities for the first time or looking to validate an existing method to ICH Q3D standards, SciSPX provides end-to-end support.

Instrument selection and application advice: Sales Engineers and Product Specialists help labs identify the right analytical instrumentation for their specific matrices, detection requirements, and throughput needs.
IQ/OQ installation and qualification: Certified Service and Support engineers perform instrument qualification in line with GMP, GLP, and 21 CFR Part 11 requirements, providing the documentation needed for regulatory submissions.
Method validation support: Application specialists work alongside lab technicians to develop and validate elemental impurity methods that satisfy pharmacopoeial and regulatory expectations.
Preventive and corrective maintenance: Ongoing service contracts keep instruments performing within specification, reducing the risk of out-of-specification results caused by equipment drift.

If your lab is preparing for a regulatory inspection, introducing a new drug product, or reviewing your current elemental impurity testing programme, contact SciSPX to discuss how we can support your compliance goals in the Benelux.

Frequently Asked Questions

How long does it take to set up and validate an elemental impurity testing method from scratch?

The timeline for setting up and validating an elemental impurity testing method varies depending on the complexity of your drug matrix and the number of elements being monitored, but most labs should plan for several weeks to a few months from instrument qualification through to full method validation. Key stages include IQ/OQ completion, method development and optimisation, and formal validation runs covering specificity, linearity, accuracy, and precision. Engaging an application specialist early in the process can significantly compress the timeline by avoiding common method development pitfalls specific to your matrix type.

What are the most common mistakes labs make when conducting an elemental impurity risk assessment?

One of the most frequent mistakes is failing to evaluate all potential sources of elemental contamination systematically, particularly indirect sources such as processing equipment, container closure systems, and excipients sourced from multiple suppliers. Another common error is treating the risk assessment as a one-time exercise rather than a living document that must be reviewed whenever there are changes to materials, suppliers, or processes. Regulatory inspectors specifically look for evidence that risk assessments are both comprehensive and actively maintained, so gaps in either area can lead to findings during GMP inspections.

Can a risk assessment alone eliminate the need for routine batch testing, and what documentation is required?

Yes, under the ICH Q3D framework a well-documented risk assessment can support a conclusion that routine batch testing for certain elements is not required, provided the assessment demonstrates with sufficient evidence that those impurities are consistently below 30% of the permitted daily exposure limit. However, this conclusion must be backed by supporting analytical data, a clear description of the evaluation methodology, and a defined review schedule. Regulatory submissions and GMP audit files should contain the full risk assessment document, the underlying data, and records of any periodic reviews to withstand scrutiny.

How should sample preparation be approached for different pharmaceutical dosage forms when using ICP-MS or ICP-OES?

Sample preparation is one of the most critical and form-specific steps in elemental impurity testing, as the matrix must be fully digested or dissolved before accurate ICP-based analysis can be performed. Solid dosage forms such as tablets and capsules typically require microwave-assisted acid digestion, while liquid formulations and injectables may be amenable to direct dilution or simpler dissolution approaches depending on their composition. It is important to validate the sample preparation procedure as part of the overall method validation, since incomplete digestion or matrix-induced signal suppression are common sources of inaccurate results.

What should a lab do if its ICP-MS instrument produces out-of-specification results during routine QC testing?

The first step is to follow your laboratory’s documented out-of-specification procedure, which should include an initial phase investigation to rule out assignable laboratory errors such as sample preparation mistakes, instrument drift, or contamination before concluding that the batch itself is non-compliant. If the OOS result is confirmed after a thorough investigation, the batch must be quarantined and a full root cause investigation initiated covering raw materials, equipment condition, and process parameters. Preventive maintenance records and instrument qualification documentation will be critical during this investigation, as they help distinguish between an equipment-related cause and a genuine product quality issue.

Are the ICH Q3D permitted daily exposure limits the same for all patient populations, or are there special considerations?

The ICH Q3D PDEs represent limits established for the general adult population, but certain patient groups warrant additional consideration, including paediatric patients, pregnant women, and individuals with impaired renal or hepatic function who may be less able to eliminate elemental impurities. For paediatric formulations in particular, regulatory guidance recommends that manufacturers apply additional safety factors when calculating acceptable impurity levels. If your drug product is intended for a vulnerable population, it is advisable to consult the relevant pharmacopoeial guidance and seek input from a regulatory affairs specialist to ensure your risk assessment adequately addresses these patient-specific factors.

How often should elemental impurity testing methods be revalidated, and what triggers a full revalidation?

Elemental impurity testing methods do not require revalidation on a fixed calendar schedule, but revalidation is triggered by any significant change that could affect method performance, such as a change in the drug formulation, a switch to a different instrument model, a change in the source or grade of reagents, or the addition of new elements to the monitoring panel. Minor changes such as updated instrument software or column lots may be handled through change control and a targeted verification study rather than full revalidation. Your change control procedure should include a formal assessment step that determines the extent of revalidation required based on the nature and risk level of the change.

This content was generated with the help of AI and it may contain mistakes